A study by Zhou and colleagues has indicated the utility of Affibody HER2-imaging in gastric cancer [73], where repeat biopsies to detect changes in HER2 expression may be particularly challenging due to the location of the lesion. Here, ERBB2 is linked to gastric cancer.